bluebird bio LLC
This article was originally published in Start Up
Executive Summary
bluebird bio LLC has taken in $65 million in venture capital over the past year, thanks to encouraging studies with two different kinds of lentiviral vectors that transfer new copies of genes into patients' own stem cells. Given that vectors have different properties - one integrates into the DNA coding region, the other does not - the company might eventually be able to mix and match therapeutic gene "fillings" to vectors as needed. The start-up is ready to start commercializing gene therapies for serious genetic disorders, starting with ALD and beta-thalassemia. .
You may also be interested in...
Bluebird’s Share Price Skyrocketing On Beta Thalassemia Optimism
On the strength of interim Phase I/II data presented at ASH and an investor presentation Dec. 10, bluebird bio is enjoying substantial growth in its stock price for the week.
Bluebird’s Improved Vector Yields Promising Early Phase II Data In Beta Thalassemia
Two patients achieve independence from transfusions and show normalizing levels of hemoglobin in Phase II trial of experimental viral vector-based gene therapy. Bluebird’s share price soared on the promising news.
Start-Up Previews (05/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Rare Disease Research: Where Compassion Meets Commerce," features profiles of Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical. Plus these Start-Ups Across Health Care: AirXpanders, Arterion, CortiCare and Sirius Implantable Systems.